You are here

Astellas

FDA changes its mind on Astellas' geographic atrophy drug

Pharmaphorum

Thu, 02/13/25 - 11:37 am

geographic atrophy

Astellas shifts investment focus to later-stage opportunities amid reprioritization

Fierce Pharma

Wed, 02/12/25 - 09:23 pm

Astellas takes $760M charge, reveals slowdown for eye drug Izervay after regulatory stumbles

Fierce Pharma

Wed, 02/5/25 - 10:54 pm

Astellas fires CSO and chief manufacturing officer in C-suite shake-up

Fierce Biotech

Tue, 02/4/25 - 09:29 am

FDA adds liver injury warning for Veozah

Beckers Hospital Review

Wed, 12/18/24 - 11:26 am

How Astellas juggles the moving parts of cancer precision medicine development

Pharma Voice

Thu, 12/5/24 - 11:05 am

precision medicine

Astellas CRL ‘clearly a positive’ for Apellis, says JPMorgan

Tip Ranks

Tue, 11/19/24 - 11:13 am

geographic atrophy

Essa abandons sole clinical-stage drug after falling short against Xtandi in phase 2 trial

Fierce Biotech

Sun, 11/3/24 - 10:17 pm

prostate cancer

Astellas doesn't see eye to eye with Europe on geographic atrophy drug Izervay

Fierce Pharma

Mon, 10/28/24 - 06:12 pm

geographic atrophy

Astellas nabs class-first FDA approval for CLDN18.2 gastric cancer med Vyloy

Fierce Pharma

Sun, 10/20/24 - 10:22 pm

Astella’s iota receives FDA go-ahead for bladder implant trial

Clinical Trials Arena

Mon, 10/14/24 - 11:16 pm

iota Biosciences

underactive bladder

clinical trials

Astellas licenses AviadoBio’s dementia gene therapy candidate

Biopharma Reporter

Fri, 10/11/24 - 09:29 am

Astellas unveils new Japan site for cell therapy research arm Universal Cells, transferring 12 roles overseas

Fierce Biotech

Wed, 10/9/24 - 09:07 pm

Astellas places $2bn+ bet on AviadoBio dementia gene therapy

Pharmaphorum

Tue, 10/8/24 - 09:44 am

frontotemporal dementia

J&J's Erleada prevails over Astellas, Pfizer’s Xtandi in real-world prostate cancer study

Fierce Pharma

Wed, 10/2/24 - 09:50 pm

prostate cancer

Astellas brings its first digital health product to US

Pharmaphorum

Fri, 09/20/24 - 10:20 am

ESMO 2024: Eli Lilly brings the competition to Novartis with new results in mCRPC

Clinical Trials Arena

Tue, 09/17/24 - 11:13 am

lutetium zadavotide guraxetan

metastatic castration-resistant prostate cancer

Astellas unveils Massachusetts lab that will be shared with biotechs, academia researchers

Fierce Biotech

Thu, 09/5/24 - 10:37 pm

Japan's Astellas says employee indicted by China's prosecutors

Reuters

Wed, 08/21/24 - 11:17 am

Astellas' gastric cancer therapy gets UK regulator's nod

Reuters

Wed, 08/14/24 - 11:19 am

monoclonal antibodies

Pages